Sykon Capital LLC Akebia Therapeutics, Inc. Transaction History
Sykon Capital LLC
- $277 Billion
- Q1 2024
A detailed history of Sykon Capital LLC transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Sykon Capital LLC holds 15,000 shares of AKBA stock, worth $22,050. This represents 0.01% of its overall portfolio holdings.
Number of Shares
15,000
Previous 15,000
-0.0%
Holding current value
$22,050
Previous $18.6 Million
47.58%
% of portfolio
0.01%
Previous 0.01%
Shares
1 transactions
Others Institutions Holding AKBA
# of Institutions
126Shares Held
56.2MCall Options Held
927KPut Options Held
743K-
Satter Management Co., L.P.13.2MShares$19.4 Million26.98% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.23MShares$12.1 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA5.31MShares$7.81 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.65MShares$5.37 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.27MShares$4.8 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $270M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...